Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

被引：4
|
作者：
Wang, Chen [1 ]
McGraw, Kathy L. [2 ]
McLemore, Amy F. [2 ]
Komrokji, Rami [2 ]
Basiorka, Ashley A. [2 ]
Al Ali, Najla [2 ]
Lancet, Jeffrey E. [2 ]
Padron, Eric [2 ]
Kosmider, Olivier [3 ]
Fontenay, Michaela [3 ]
Fenaux, Pierre [4 ]
List, Alan F. [2 ]
Sallman, David A. [2 ]
机构：
[1] Univ S Florida, Dept Internal Med, Morsani Coll Med, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[3] Ctr Univ Paris, Serv Hematol Biol, Hop Cochin, Assistance Publ Hop Paris, Paris, France
[4] Hop St Louis, Grp Francophone Myelodysplasies, Paris, France
来源：
HAEMATOLOGICA | 2022年 / 107卷 / 03期
关键词：
MECHANISM;
D O I：
10.3324/haematol.2021.278855
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：737 / 739
页数：3
相关论文
共 50 条
  • [21] Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
    Almeida, Antonio
    Santini, Valeria
    Croepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Mufti, Ghulam J.
    Sanz, Guillermo
    Skikne, Barry
    Hoenekopp, Albert
    Seguy, Francis
    Zhong, Jianhua
    Fenaux, Pierre
    BLOOD, 2015, 126 (23)
  • [22] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [23] Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
    Hong, Junshik
    Lee, Yoo Jin
    Bae, Sung Hwa
    Yi, Jun Ho
    Park, Sungwoo
    Chang, Myung Hee
    Park, Young Hoon
    Hyun, Shin Young
    Chung, Joo-Seop
    Jang, Ji Eun
    Jung, Joo Young
    Jeon, So-Yeon
    Song, Seo-Young
    Kim, Hawk
    Kim, Dae Sik
    Kim, Sung-Hyun
    Kim, Min Kyoung
    Han, Sang Hoon
    Park, Seonyang
    Kim, Yoo-Jin
    Lee, Je-Hwan
    BLOOD RESEARCH, 2021, 56 (02) : 102 - 107
  • [24] Increases In Mirna-145 and Mirna-146a Expression In Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide
    Oliva, Esther Natalie
    Nobile, Francesco
    Iacopino, Pasquale
    Alimena, Giuliana
    Di Raimondo, Francesco
    Palumbo, Giuseppe A.
    Lagana, Carmelo
    D'Errigo, Maria Grazia
    Latagliata, Roberto
    Cuzzola, Maria
    BLOOD, 2010, 116 (21) : 1494 - 1494
  • [25] A computational biology method to predict HMA or lenalidomide treatment response in non-Del(5q) MDS
    Drusbosky, Leylah
    Singh, Neeraj Kumar
    Vali, Shireen
    Abbasi, Taher
    Cogle, Christopher R.
    CANCER RESEARCH, 2017, 77
  • [26] Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
    Mallo, Mar
    del Rey, Monica
    Ibanez, Mariam
    Jose Calasanz, Ma
    Arenillas, Leonor
    Jose Larrayoz, Ma
    Pedro, Carmen
    Jerez, Andres
    Maciejewski, Jaroslaw
    Costa, Dolors
    Nomdedeu, Meritxell
    Diez-Campelo, Maria
    Lumbreras, Eva
    Gonzalez-Martinez, Teresa
    Marugan, Isabel
    Such, Esperanza
    Cervera, Jose
    Cigudosa, Juan C.
    Alvarez, Sara
    Florensa, Lourdes
    Hernandez, Jesus Ma
    Sole, Francesc
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 74 - 86
  • [27] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
  • [28] Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?
    Shallis, Rory M.
    Zeidan, Amer M.
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2015 - 2017
  • [29] Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial
    Garcia-Manero, Guillermo
    Almeida, Antonio
    Fenaux, Pierre
    Gattermann, Norbert
    Giagounidis, Aristoteles
    Goldberg, Stuart L.
    Ozawa, Keiya
    Weaver, Jerry
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 213 - +
  • [30] Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study
    Diez-Campelo, Maria
    Yucel, Aylin
    Goyal, Ravi K.
    Parikh, Rohan C.
    Esterberg, Elizabeth
    Jimenez, Maria
    Sluga-O'Callaghan, Martina
    Miteva, Dimana
    Xiao, Hong
    Germing, Ulrich
    BLOOD, 2022, 140 : 13308 - 13309
12345